Abstract
Abnormalities in the tumor suppressor TP53 are among the most common mechanisms of cancer pathogenesis (Lane and Levine 2010) and formed the rationale for TP53 gene therapy to restore normal p53 function in cancer treatment. Several important principles were elucidated in preclinical tumor models which predicted the outcomes of subsequent clinical trials including synergistic antitumor activity for combined TP53 gene therapy plus DNA damaging chemotherapy and radiation (Zhang and Roth 1994; Gjerset and Sobol 1997; Nielsen and Maneval 1998).
Cite
CITATION STYLE
Sobol, R. E., Guan, Y. S., Li, L. J., Zhang, W. W., Peng, Z., Menander, K. B., … Roth, J. A. (2013). Tp53 gene therapy for cancer treatment and prevention. In p53 in the Clinics (pp. 189–208). Springer New York. https://doi.org/10.1007/978-1-4614-3676-8_11
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
